Intedrated Imagaing and Tissue Biomarkers in Glioblastoma Multiforme Post Therapy

多形性胶质母细胞瘤治疗后的综合成像和组织生物标志物

• 批准号: 7303485
• 负责人: Susan M Chang
• 金额: $ 21.96万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7303485
• 关键词: Aftercare; Anatomy; Area; Behavior; Biological; Biological Markers; Biology; Blood Volume; Brain; Cerebrum; Characteristics; Choline; Clinical; Clinical Research; Clinical Services; Clinical Trials; Clinical Trials Design; Convection; Data; Diagnosis; Diffusion; Disease Progression; End Point; Evaluation; Functional Imaging; Glioblastoma; Growth; Histologic; Image; Invasive; Liposomes; Magnetic Resonance; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Metabolic; Methods; Modeling; Numbers; Operative Surgical Procedures; Outcome; Pathologic; Patient Care; Patients; Perfusion; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Physiological; Property; Purpose; Recurrence; Recurrent tumor; Relative (related person); Sampling; Scanning; Secondary to; Specialized Program of Research Excellence; Specimen; Standards of Weights and Measures; Time; Tissues; Toxic effect; Tumor Biology; clinically relevant; design; indexing; insight; intraoperative imaging; irinotecan; nano; neoplastic cell; neuro-oncology; neuroimaging; novel; prospective; response; treatment effect; tumor; tumor progression

The objective of this project is to determine whether the integration of quantitative characteristics derived rom neuroimaging parameters (magnetic resonance spectroscopic indices, cerebral blood volume and apparent diffusion coefficient), with tissue biomarkers and are predictive of the biologic behavior for patients with glioblastoma multiforme (GBM) post therapy. Standard magnetic resonance imaging (MRI) is limited in assessing the biological behavior of increased enhancement which universally occurs post therapy. Although in the majority of cases this is secondary to tumor progression, following focal therapies such as convection enhanced delivery(CED) of agents, increased enhancement could be secondary to treatment effects. Pathologic specimens obtained post therapy in areas of new enhancement often consist of both 'tumor" and " treatment effect". There are currently no well-established biomarkers that distinguish between tumor or treatment effect or are predictive of the behavior of the radiographic changes post therapy. In this project the objectives will be accomplished by the evaluation of metabolic and physiologic imaging parameters to differentiate between treatment related changes and recurrent tumor. If physiologic imaging can be correlated with tumor biology or clinical outcome, this will allow for the repeated use of a safe, non- invasive, easily acquired biomarker. This will have significant implications to the care of patients and the design, conduct and interpretation of clinical trials in Neuro-Oncology. Patients with radiographically defined progression" will be studied prior to treatment for recurrence and followed for clinical outcome to determine if specific parameters are predictive of biological behavior. This information will give insight into the imaging methods required for evaluation of the effects of CED of a novel compound and prospective physiologic imaging is planned before and after treatment in a clinical trial of CED. These studies will require the support of the Clinical Services Core and the Imaging and Tissue Correlate Core

本项目的目标是确定是否整合了量化特征 ROM神经成像参数（磁共振波谱指数、脑血容量和 表观扩散系数）与组织生物标志物，可预测患者的生物学行为 多形性胶质母细胞瘤（GBM）。标准磁共振成像（MRI）在以下方面受到限制： 评估治疗后普遍发生的增强的生物学行为。 尽管在大多数情况下，这是继发于肿瘤进展，但在局部治疗后， 药物的对流增强输送（CED），增强可能继发于治疗 方面的影响.治疗后在新增强区域获得的病理标本通常包括两者 “肿瘤”和“治疗效果”。目前还没有成熟的生物标志物来区分 肿瘤或治疗效果，或者预测治疗后放射学变化的行为。在这 该项目的目标将通过评估代谢和生理成像来实现 参数来区分治疗相关变化和复发肿瘤。如果生理成像 可以与肿瘤生物学或临床结果相关，这将允许重复使用安全，非- 侵入性，容易获得的生物标志物。这将对病人的护理和病人的健康产生重大影响。 神经肿瘤学临床试验的设计、实施和解释。放射学定义的患者 将在治疗复发之前研究“进展”，并随访临床结局，以确定 如果特定的参数可以预测生物行为。这些信息将使我们深入了解 评价新型化合物和前瞻性生理学药物CED效果所需的方法 在CED的临床试验中，计划在治疗之前和之后进行成像。这些研究将需要 临床服务核心和成像与组织相关核心